Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Haematological malignancies

204MO - Patterns of treatment and outcomes in CLL patients in Australia: An analysis of the population-wide pharmaceutical benefits scheme dataset


04 Dec 2022


Mini Oral session: Haematological malignancies


Tumour Site

Haematological Malignancies


Constantine Tam


Annals of Oncology (2022) 33 (suppl_9): S1515-S1520. 10.1016/annonc/annonc1127


C. Tam1, F. Zhao2, R. Gauba3, M.H. Kouhkamari4, S.C. Li5, B. Tang6

Author affiliations

  • 1 Lymphoma Service, Alfred Health, Monash University, 3004 - Melbourne/AU
  • 2 Heor, Medical Affairs Department, BeiGene, Ltd., 2000 - Sydney/AU
  • 3 Medical Department, BeiGene Australia Pty. Ltd., 2000 - Sydney/AU
  • 4 Rwe, Prospection Pty Ltd, Sydney/AU
  • 5 Biomedical Sciences And Pharmacy, The University of Newcastle, 2308 - Callaghan/AU
  • 6 Heor, Medical Affairs Department, BeiGene, Ltd., 94403 - San Mateo/US


Login to access the resources on OncologyPRO.

Abstract 204MO


There is limited information on the chronic lymphocytic leukaemia (CLL) patient characteristics and outcomes, or the treatment strategies adopted for its management in the Australian real-world setting. This study aimed to describe the treatment patterns and outcomes of people with CLL who received treatment under the Pharmaceutical Benefits Scheme (PBS).


This retrospective study included patients who initiated CLL treatment between 2011/01/01 and 2021/07/31 with data extracted from the 10% PBS dataset. The dataset contains the dispensing records for 10% of the Australian population and captures all publicly funded treatments. Outcomes of interest were treatment patterns, duration of therapy, time to next treatment (TTNT), and overall survival (OS). The first medication used for CLL was designated as the index date. The Kaplan-Meier (KM) method was used to analyse the duration of therapy, TTNT and OS. The effects of baseline patient characteristics and comedications were explored with sub-group sensitivity analyses and Cox proportional hazards regression analyses wherever feasible.


Of 803 CLL patients included, most patients were male (65%) and >60 years (77%). Treatment trends have changed over the last 10 years. In the frontline setting, fludarabine-chlorambucil-rituximab use has decreased while chlorambucil + CD20 agents usage has increased. In the relapsed/refractory (R/R) setting, CD20 monotherapy has decreased and BTKi and venetoclax ± CD20 usage has increased. In the overall cohort, the median TTNT was 30 months (95%CI, 25-35). The median duration of ibrutinib therapy was 24 months (95%CI, 19-38) and 19 months (95%CI, 11-not reached (NR)) for venetoclax. Median OS was 127 (95%CI, 105-NR) and 94 months (95%CI, 74-NR) in front-line and R/R patients respectively. For the sub-cohort with R/R CLL initiating treatment after Nov 2017 (the first BTKi listing on the PBS) (n=114), the median OS was not reached yet.


In the Australian setting, CLL treatment patterns have significantly changed since the introduction of novel therapies. Median OS in the front-line setting is more than 10 years, while the R/R population has a shorter OS observed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study





C. Tam: Financial Interests, Personal, Advisory Role: BeiGene; Financial Interests, Personal, Other, Honoraria: AbbVie, Janssen, BeiGene; Financial Interests, Institutional, Research Grant: AbbVie, Janssen, BeiGene. F. Zhao, R. Gauba, B. Tang: Financial Interests, Institutional, Full or part-time Employment: BeiGene; Financial Interests, Institutional, Stocks/Shares: BeiGene. M.H. Kouhkamari: Financial Interests, Institutional, Full or part-time Employment: Prospection; Financial Interests, Institutional, Other, Consulting, Prospection is a consulting service provider: Pharma companies in Australia. S.C. Li: Financial Interests, Personal, Advisory Role: BeiGene.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.